Analysis of <i>Fusobacterium</i> persistence and antibiotic response in colorectal cancer

Susan Bullman(Broad Institute), Chandra Sekhar Pedamallu(Broad Institute), Ewa Sicińska(Harvard University), Thomas E. Clancy(Brigham and Women's Hospital), Xiaoyang Zhang(Broad Institute), Diana Cai(Broad Institute), Donna Neuberg(Harvard University), Katherine Huang(Broad Institute), Fatima Guevara(Harvard University), Timothy Nelson(Harvard University), Otari Chipashvili(Harvard University), Timothy Hagan(Harvard University), Mark Walker(Broad Institute), Aruna Ramachandran(Broad Institute), Begoña Diosdado(Broad Institute), Garazi Serna(Hebron University), Nuria Mulet(Hebron University), Stefania Landolfi(Hebron University), Santiago Ramón y Cajal(Hebron University), Roberta Fasani(Hebron University), Andrew J. Aguirre(Broad Institute), Kimmie Ng(Harvard University), Elena Élez(Hebron University), Shuji Ogino(Brigham and Women's Hospital), Josep Tabernero(Hebron University), Charles S. Fuchs(Yale Cancer Center), William C. Hahn(Broad Institute), Paolo Nucíforo(Hebron University), Matthew Meyerson(Broad Institute)
Science
November 23, 2017
10.1126/science.aal5240
Cited by 1,503

Abstract

Bacteria go the distance in cancer The bacterial species Fusobacterium nucleatum is associated with a subset of human colorectal cancers, but its role in tumorigenesis is unclear. Studying patient samples, Bullman et al. found that F. nucleatum and certain co-occurring bacteria were present not only in primary tumors but also in distant metastases. Preliminary evidence suggests that the bacterium is localized primarily within the metastatic cancer cells rather than in the stroma. Antibiotic treatment of mice carrying xenografts of F. nucleatum –positive human colorectal cancer slowed tumor growth, consistent with a causal role for the bacterium in tumorigenesis. Science , this issue p. 1443

Related Papers

No related papers found

Powered by citation graph analysis